To which session should I apply?

PLENARY SESSION
Biopharma industry has been facing uncertainties in 2023:
What is the impact for early-stage partnering and financing strategies?

The current economic and geopolitical contexts have been difficult for innovation around the world and life sciences are no exception. In a period of inflation, war, high energy prices and financial strains, investments have been shrinking. This session will explore the specific challenges facing the sector and strategies for making the most of the current reality to ensure that biotech innovation continues to be funded and thrive in a complex landscape.

What are the current key issues in the EU biotech ecosystem compared to the US, particularly with regard to drug pricing pressure? What has been the support of public and non-profit organisations to the sector? How has the reduced ability of funds to raise money impacted on the availability of capital in the short to medium term? To what extent does the decline in asset prices impact on the external innovation strategies of pharmaceutical companies? How does balancing the need for innovation with financial viability allow for broader sources of innovation and the structuring of new early-stage collaborations? What is the outlook for life sciences dealmaking in 2024?

Different options to participate in BioFIT:

Take advantage of the Super Early Bird offer before it’s too late,
benefit from a lower rate to book a stand and:

1️⃣​ Enhance your visibility among innovative leaders in the sector gathering at BioFIT
2️⃣​​ Maximise your business opportunities, expand your network and showcase your assets
3️⃣​ Highlight your company thanks to descriptions on our communication tools
4️⃣ Secure your spot: places are limited and assigned on a first-come, first-served basis